Treatment of proliferative and membranous lupus nephritis: Review of key clinical trials

American Journal of the Medical Sciences

Volumn 343, Issue 1, 2012, Pages 86-90

  Alshayeb, Hala ^a   Wall, Barry M ^a,b   Gosmanova, Elvira O ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Division of Nephrology   (United States)

Author keywords

Lupus nephritis; Treatment

Indexed keywords

ABATACEPT; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; EPRATUZUMAB; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADD ON THERAPY; AMENORRHEA; B LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG TREATMENT FAILURE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE MIGRATION; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH ORGANIZATION; NONHUMAN; OVARY INSUFFICIENCY; PLASMAPHERESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT;

EID: 84855286469     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31821996ca     Document Type: Review

References (42)

1. Dooley MA. Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia (PA): Lippincott Williams & Wilkins; 2007. p. 1112-30.
2. Cervera R, Khamashta MA, Font J, et al. European Working Party on systemic lupus erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period. A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82:299-308. (Pubitemid 37229465)
3. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40. (Pubitemid 39643941)
4. Ponticelli C, Moroni G. Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 1998;7:635-8. (Pubitemid 29008231)
5. Moroni G, Quaglini S, Maccario M, et al. 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047-53. (Pubitemid 26417549)
6. Fiehn C, Hajjar Y, Mueller K, et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003;62:435-9. (Pubitemid 36469735)
7. Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9. (Pubitemid 16132725)
8. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
9. Boumpas DT, Austin HA 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
10. Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57. (Pubitemid 126450087)
11. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57. (Pubitemid 32799338)
12. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7. (Pubitemid 28225783)
13. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 1995;38:1120-7.
14. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
15. Dooley MA, Hogan S, Jennette C, et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997;51:1188-95. (Pubitemid 27186545)
16. Van Bruggen MC, Walgreen B, Rijke TP, et al. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998;9:1407-15. (Pubitemid 28354550)
17. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118. (Pubitemid 30394534)
18. Eugui EM, Almquist SJ, Muller CD, et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33:161-73.
19. Hauser IA, Renders L, Radeke HH, et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999;14:58-63. (Pubitemid 29041868)
20. Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999;31:1250-2. (Pubitemid 29127892)
21. Lui SL, Chan LY, Zhang XH, et al. Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischaemia-reperfusion injury. Nephrol Dial Transplant 2001;16:1577-82. (Pubitemid 32750448)
22. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
23. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84. (Pubitemid 41710318)
24. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28. (Pubitemid 41697285)
25. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
26. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 2010;49:128-40.
27. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80. (Pubitemid 38269274)
28. Houssiau FA, Cruz DD', Sangle S, et al. Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis: results of a randomized trial. Ann Rheum Dis 2010;69:2083-9.
29. Jayne D, Appel G, Dooley M, et al. Results of Aspreva Lupus Management Study (ALMS) Maintenance Phase. Renal Week 2010: Abstract TH-FC111.
30. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
31. Catapano F, Chaudhry AN, Jones RB, et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010;25:3586-92.
32. Moroni G, Gallelli B, Banfi G, et al. Rituximab monotherapy for remission induction of proliferative lupus nephritis flares: description of 3 cases. J Nephrology 2010;23:357-61.
33. Goldberg A, Katzap E. Belimumab for the treatment of systemic lupus erythematosus. Int J Clin Rheum 2010;5:407-13.
34. Lateef A, Petri M. Biologicals in treatment of SLE. Curr Opin Rheumatol 2010;22:504-9.
35. Dörner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74.
36. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7. (Pubitemid 24291979)
37. Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephrotis Collaborative Study Group. N Engl J Med 1992;326:1373-9.
38. Sloan RP, Schwartz MM, Korbet SM, et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996;7:299-305. (Pubitemid 26092479)
39. Austin HA 3rd, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901-11.
40. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
41. Mok CC, Ying KY, Lau CS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004;43:269-76. (Pubitemid 38146325)
42. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010;21:2028-35.